Comparative Pharmacology
Head-to-head clinical analysis: VIGABATRIN versus ZONEGRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGABATRIN versus ZONEGRAN.
VIGABATRIN vs ZONEGRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
Anticonvulsant; blocks voltage-gated sodium and calcium channels, enhances GABA-mediated inhibition, and inhibits glutamate release.
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
Initial: 100 mg orally once daily for 2 weeks, then may increase by 100 mg/day at 2-week intervals; usual maintenance: 200-400 mg/day divided once or twice daily; maximum: 600 mg/day.
None Documented
None Documented
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
Clinical Note
moderateVigabatrin + Venlafaxine
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine."
Clinical Note
moderateVigabatrin + Nefazodone
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone."
Clinical Note
moderateVigabatrin + Stiripentol
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol."
Clinical Note
moderateVigabatrin + Clomipramine
Terminal elimination half-life is approximately 63 hours (range 50-70 hours) in adults. The long half-life allows for once- or twice-daily dosing. Steady state is reached after about 2 weeks of repeated dosing.
Renal: ~80% unchanged in urine; fecal: <5%.
Renal: approximately 62% of the dose as unchanged drug and metabolites (primarily glucuronide conjugates and N-acetylzonisamide). Fecal: approximately 16% (including metabolites). Biliary excretion is minimal. Total recovery in urine and feces accounts for ~80% of the dose.
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine."